This biographical article is written
like a résumé. (March 2014) |
Ihor R. Lemischka was an American stem cell biologist and stem cell research advocate [1] and was both the Lillian and Henry M. Stratton Professor of Gene and Cell Medicine and Director of the Black Family Stem Cell Institute at Mount Sinai Medical Center in New York City. [2]
His work with hematopoietic stem cells (HSC) was the first to identify their novel receptor tyrosine kinases and showed that HSC can rebuild all blood cell types in a mouse whose blood cells had been destroyed. [3] [4]
He authored over 70 book chapters and publications in peer-reviewed journals. [5]
Lemischka graduated from Johns Hopkins University in 1976 [6] and earned his Ph.D in biology from MIT in 1983. He did his post-doctoral training at MIT's Whitehead Institute.
Lemischka joined Princeton University in 1986 as Assistant Professor of Molecular Biology; he became Professor in 2002. [5] In 2007, he joined the staff at Mount Sinai Medical Center, where he was Professor of Gene and Cell Medicine and Director of the Black Family Stem Cell Institute.
Lemischka was a board member of the International Society for Stem Cell Research, the Journal of Visualized Experiments (JoVE) and the New York Stem Cell Foundation. His awards included a Damon Runyon-Walter Winchell Postdoctoral, a Leukemia Social Special Fellowship, an American Cyanamid Preceptorship Award and the DuPont Young Faculty Grant. [5] He was a journal reviewer for Cell, Science, Nature, Nature Genetics, Nature Immunology, Nature Biotechnology, Proceedings of the National Academy of Sciences, Public Library of Science, Development, Genes & Development, Journal of Clinical Investigation and Blood.
Lemischka held or had patents pending for the following: [7]
Patent Number | Title |
---|---|
7465464 | Populations of cells that express flk-2 receptors |
7445798 | Populations of cells that express FLK-1 receptors |
6960446 | Method for isolating cells expressing flk-2 |
6677434 | Soluble human flk-2 protein |
6613565 | Use of delta-like protein to inhibit the differentiation of stem cells |
5912133 | Method for isolating stem cells expressing flk-1 receptors |
5747651 | Antibodies against tyrosine kinase receptor flk-1 |
5621090 | Nucleic acids encoding soluble human FLK-2 extracellular domain |
5548065 | Tyrosine kinase receptor human flk-2-specific antibodies |
5367057 | Tyrosine kinase receptor flk-2 and fragments thereof |
5283354 | Nucleic acids encoding hematopoietic stem cells receptors flk-1 |
5270458 | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
5185438 | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
Lemischka's interests included defining the cellular and molecular mechanisms that control cell fate decisions in embryonic stem cells. Research into mouse embryonic stem cells was aggressively studied in the embryonic stem cells of humans. [8]
Partial List: